MDT Stock Price Today (July 2026) — MDT Analysis & Key Metrics 2026-07-17
MDT (MDT) is trading at $83.20, down 0.43% today (as of July 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Software growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $97.77 (17.5% upside).
- Volatility remains elevated (34.56% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.90% YoY) alongside significant competitive pressures.
MDT Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
MDT - Historical Price & Volume
Market Cap
Enterprise Value: $120.68B
P/E Ratio
Forward P/E: 12.21
Revenue Growth
Year over Year
Analyst Target
+17.5% upside potential
Key Investor Questions About MDT
What investors need to know before buying
Based on current market data, MDT presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 55.50)
- Fundamentals say: Caution warranted (high leverage concerns)
MDT's growth trajectory depends on its ability to expand within the Software sector while managing margin pressures.
- Future growth will depend on performance in core Software operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MDT investors include debt exposure and competitive dynamics in the Software industry.
- $29.15B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Software.
52-Week Trading Range
Over the past year, MDT stock traded between $73.31 and $106.33—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 34.56% annualized volatility and β=0.40, the stock exhibits low sensitivity to market moves—making MDT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Abbott Just Showed Its Growth Engine Has More Than One Cylinder
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years
Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.
Can Abbott Stock Deliver on Its Second-Half Growth Promise?
This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.
Medtronic completes SPR Therapeutics acquisition
Medtronic bought the pain company to expand in neuromodulation, one of its areas of strategic focus and investment.
RapidPulse obtains funding for stroke aspiration system
The new capital will enable completion of the multi-centre investigational device exemption trial, TURBO.
Medtronic (MDT) Completes SPR Therapeutics Deal To Expand Non Opioid Pain Care
Medtronic (NYSE:MDT) has completed its acquisition of SPR Therapeutics. The deal adds a minimally invasive, non opioid treatment option for chronic and acute pain to Medtronic's pain therapy portfolio. For investors watching Medtronic, this move expands the company's presence in pain care beyond its existing device lineup. SPR Therapeutics focuses on peripheral nerve stimulation, a therapy that fits into a broader push across healthcare to reduce reliance on opioid medications for pain...
How Medtronic’s (MDT) Targeted Device Recall and Earnings Beat Have Changed Its Investment Story
In May 2026, Medtronic voluntarily initiated a Class II recall of 590 Octopus 4 Tissue Stabilizer devices after discovering an assembly issue in the tubing configuration, with the US FDA now listing the action as an ongoing enforcement event affecting worldwide distribution. Around the same time, Medtronic’s fiscal Q3 2024 results exceeded earnings and revenue expectations, drawing attention to how the company balances quality-control challenges with operational and financial...
Why Abbott Stock Is Reimagining Its Future
Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.
The Real Engine Behind Johnson & Johnson Stock's Next Climb
While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.
Frequently Asked Questions
Common investor questions about MDT
MDT (MDT) is currently trading at $83.20. The RSI (14-day) is at 55.5, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $97.77 implies 17.5% upside from current levels. Volatility is moderate at 34.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for MDT (MDT): The trailing P/E ratio is 22.31, which is in line with broader market averages. The forward P/E is 12.21, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.54, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.15. Price-to-Sales is 2.93. Valuation should be compared to Software industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering MDT, the consensus price target is $97.77. This represents a 17.5% upside from the current price of $83.20. The range spans from a low target of $78.00 to a high target of $121.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, MDT (MDT) pays a dividend with a current yield of approximately 3.46%. The annualized dividend rate is $2.84 per share. The payout ratio is 76.1%, which is relatively high—earnings cover the dividend but there's limited room for increases. The most recent ex-dividend date was 2026-06-26T00:00:00.000Z.
Key risks for MDT (MDT) investors include: 1. Moderate volatility (34.6% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Software sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is MDT's (MDT) current debt and financial health profile: Total debt stands at $29.15B. The debt-to-equity ratio is 58.21, which is moderate and generally manageable for most companies. The current ratio is 2.13, indicating strong short-term liquidity. The quick ratio is 1.36. The company holds $9.22B in cash and equivalents. Free cash flow is positive at $4.63B, providing a cushion for debt servicing and shareholder returns.